Published Research
The following academic papers on Ewing sarcoma have been published in peer-reviewed journals. Click on the links to read a summary of each paper.
2015
Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing
Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA
2014
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial
Marie-Cécile Le Deley⇑, Michael Paulussen, Ian Lewis, Bernadette Brennan, Andreas Ranft, Jeremy Whelan, Gwénaël Le Teuff, Jean Michon, Ruth Ladenstein, Perrine Marec-Bérard, Henk van den Berg, Lars Hjorth, Keith Wheatley, Ian Judson, Heribert Juergens, Alan Craft, Odile Oberlin and Uta Dirksen
2012
Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other Small Round Cell Sarcomas
Jeremy Whelan, Atia Khan, Anand Sharma, Christian Rothermundt, Palma Dileo, Maria Michelagnoli, Beatrice Seddon, and Sandra Strauss
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR.
2010
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H
2006
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A
2003
Single Center Experience of a New Intensive Induction Therapy for Ewing’s Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties
S.J. Strauss, A. McTiernan, D. Driver, M. Hall-Craggs, A. Sandison, A.M. Cassoni, A. Kilby, M. Michelagnoli, J. Pringle, J. Cobb, T. Briggs, S. Cannon, J. Witt and J.S. Whelan